Obesity is known to be an important risk factor for a whole range of noncommunicable diseases that include type 2 diabetes mellitus (T2DM), chronic obstructive sleep apnoea, various types of cancers (for example, colo rectal cancer, oesophagus and breast cancer after the menopause) and NAFLD. Although the fact that obesity increases risk of certain diseases is well accepted by clinicians, evidence has shown that some individuals who are obese are also metabolically healthy: socalled meta bolically healthy obesity (MHO). In a retro spective cohort study involving metab olically healthy individuals, Chang et al. 1 found that BMI categories are positively associated with an increased incidence of NAFLD, suggesting that the obese phenotype, regardless of meta bolic abnormalities, might increase the risk of developing NAFLD.
Increasing evidence suggests that BMI, the most common proxy measure used to help categorize overweight or obesity, is an imprecise measure of bodyfatrelated risk of noncommunicable diseases. Rather, other features associated with overweight or obesity, such as visceral fat mass, adipose tissue inflammation, adipose tissue function, or factors such as insulin resistance and meta bolic syndrome components, might be the key pathogenetic aspects that mediate increased risk of noncommunicable diseases in individ uals with overweight or obesity (TABLE 1) . Nevertheless, the concept of MHO has gained much interest in the scientific community.
with MHO have lower risk of allcause and causespecific mortality [2] [3] [4] . Furthermore, studies suggest that individ uals with MHO have similar insulin sensitivity to lean individ uals, as well as lower liver fat content and lower intimalmedial thickness of the carotid artery compared with individuals who are MAO 5, 6 . Agreement on a universally accepted definition of MHO, however, would improve the design of future studies and would facilitate comparisons between studies.
Obesity is a much stronger risk factor for T2DM than for cardiovascular disease, sug gesting that there could be differential effects of fat mass, fat function or other obesity related cardiometabolic risk factors in these two different noncommunicable diseases. Researchers have increasingly been investig ating relationships between obesity and NAFLD, and the consequent negative effects of NAFLD on risk of T2DM and cardio vascular disease. Although NAFLD has been known for many years to increase the risk of developing chronic liver disease and hepato cellular carcinoma, it is now evident that NAFLD is also an important risk factor for extrahepatic diseases, such as cardiovascular disease and T2DM 7 . Previously, one study examined the crosssectional association between obesity and NAFLD using data from a large Korean occupational cohort, and showed that the prevalence of ultrasonographydiagnosed MHO is a complex, emerging phenotype with risks intermediate between metabolically healthy individuals with normalweight and individuals who are metabolically abnormal with obesity (MAO). Compared with meta bolically healthy individuals with normal weight, individuals with obesity are at an increased risk of allcause and causespecific mortality and cardiovascular disease events even in the absence of metabolic abnormali ties, suggesting that there is no healthy pattern of increased weight [2] [3] [4] . However, compared with their peers who are MAO, individuals
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Obesity is a risk factor for several noncommunicable diseases, but some individuals with obesity remain metabolically healthy throughout life; whether these individuals are at risk of developing NAFLD is uncertain. In a new study, Chang et al. showed a statistically significant, graded relationship between BMI and NAFLD in metabolically healthy individuals. . Using data from the same occupa tional cohort, Chang et al.
1 have now devel oped the work further and have undertaken a retrospective cohort study to examine relationships between BMI categories and incident NAFLD, having excluded patients who were metabolically abnormal at base line (defined as having no metabolic syn drome components and a homeostasis model assessment of insulin resistance of less than 2.5)
1 . The researchers studied 77,425 men and women who were free of NAFLD, with the presence of NAFLD again determined using ultrasonography. During the 4.5 years of followup, 10,340 participants developed NAFLD. In a multivariable adjusted regres sion model, the hazard ratios for incident NAFLD, comparing participants who were overweight and obese with participants with normalweight were 2.15 (95% CI 2.06-2.26) and 3.55 (95% CI 3.37-3.74), respectively. Importantly, increasing baseline BMI showed a strong and approximately linear positive relationship with the incidence of NAFLD, suggesting that any amount of excess body fat increased the risk of developing NAFLD 1 .
Patients with NAFLD are known to have an increased risk of both liverrelated and cardiovascular disease mortality 7 , but it is unclear how BMI in this patient group influences risk of NAFLDrelated mortality. Controversy persists among researchers as to the optimum BMI for lowest mortality in the general population. Optimal BMI levels for the minimization of allcause mortal ity will probably vary by age, ethnicity and the proportion of people with comorbidity (such as NAFLD) in different populations. A detailed metaanalysis of 230 prospec tive studies with 3.74 million deaths among >30 million partici pants has also provided further evidence that adiposity (measured by BMI) increases the risk of premature mor tality 9 , in which the lowest mortality was observed at a BMI of ~25 kg/m 2 . The relative effect of different BMIs on health in people with different comorbidities such as NAFLD, however, needs clarification. This information would be extremely helpful both for health care professionals and for the patients with these comorbidities. Owing to the occurrence of secular trends in BMI over time that also influence the relationship between BMI and mortality outcomes, contemporaneous data (rather than historical evidence) is needed to better understand relation ships between BMI and noncommunicable diseases such as NAFLD. One interesting study in a Danish cohort clearly demonstrated that the BMI associated with lowest allcause mortality had increased by 3.3 kg/m 2 between 1976 and 2013 (REF. 10 ). Given that BMI measurement is a crude proxy for the adipo sity levels in an individual and has different implications in the presence or absence of other meta bolic risk factors, one option for redefining healthy BMI categories for adults would be to use standardized BMIforage zscores based on contemporary population distrib utions for men and women (separately) of different ethni city and age groups, similar to the zscore approach used to identify obesity among children. Furthermore, as weight gain often occurs in individuals at different times during life, major challenges exist for finding effective ways to prevent weight gain, sup port weight loss and prevent weight regain, to influence risk of developing NAFLD.
In conclusion, Chang et al. 1 showed that increasing BMI is independently associated with an increased incidence of NAFLD in a cohort of strictly defined metabolically healthy men and women. The study adds to the increasing body of evidence that overweight and obesity are much stronger risk factors for NAFLD than for other noncommunicable diseases, such as cardiovascular disease.
Future large prospective studies are needed to examine the transition between MHO and MAO phenotypes and whether genet ics and lifestyle factors play a part in both develop ment and reversal of such pheno types. Furthermore, additional research is also needed to better elucidate how the transition between MHO and MAO pheno types might affect the severity of NAFLD histology. Finally, future inquiries should also target genetic studies to investigate why certain individ uals with obesity do not seem to develop the metabolic abnormalities associated with obesity.
